PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen

PDS Biotechnology (NASDAQ:PDSB) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

PDSB has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of PDS Biotechnology in a research report on Wednesday, April 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.00.

PDS Biotechnology Trading Down 2.7%

PDS Biotechnology stock opened at $0.68 on Friday. The stock has a 50-day moving average price of $0.94 and a 200 day moving average price of $0.89. The company has a market capitalization of $38.11 million, a price-to-earnings ratio of -1.02 and a beta of 1.59. The company has a quick ratio of 2.26, a current ratio of 2.26 and a debt-to-equity ratio of 2.73. PDS Biotechnology has a 52 week low of $0.51 and a 52 week high of $1.55.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. Sell-side analysts anticipate that PDS Biotechnology will post -0.52 EPS for the current year.

Institutional Trading of PDS Biotechnology

Several large investors have recently bought and sold shares of PDSB. Tempus Wealth Planning LLC lifted its stake in PDS Biotechnology by 29.3% in the 4th quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock worth $48,000 after purchasing an additional 14,000 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $92,000. Susquehanna International Group LLP increased its holdings in shares of PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares during the last quarter. Armistice Capital LLC purchased a new position in PDS Biotechnology during the fourth quarter worth approximately $2,182,000. Finally, Geode Capital Management LLC boosted its stake in PDS Biotechnology by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after buying an additional 38,399 shares during the last quarter. Hedge funds and other institutional investors own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.